Navigation Links
Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings
Date:4/5/2011

PARSIPPANY, N.J., April 5, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, announced today that the Company intends to release its first quarter 2011 financial results on Wednesday, April 27, 2011 prior to the open of the U.S. financial markets.  The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on April 27, 2011 to discuss its financial results and provide an update on the Company's outlook for 2011.  The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on May 11, 2011.  The replay may be accessed by dialing (800) 642-1687 and entering pass code 56748589.  From international locations, the replay may be accessed by dialing (706) 645-9291 and entering the same pass code.  To access the webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.  A replay of the webcast will also be available.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press releases and other company information, visit the Watson Web site at http://www.watson.com

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:
Investors:
Patty Eisenhaur
Watson Ph
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... GRONINGEN, The Netherlands , June 22, 2010 ... announced this week that in collaboration,with the University ... for the treatment of inhalation anthrax. In a rabbit ... time to treatment (48h post,infection) with a combination of ...
... June 21 Lexicon Pharmaceuticals, Inc. ... breakthrough treatments for human disease, presented clinical data and analysis ... for patients with type 2 diabetes mellitus at ENDO 2010 ... trend of increased total GLP-1 in both LX4211 treatment arms ...
Cached Medicine Technology:Survival Rate Up to 100% for Late Stage Treatment of Anthrax Infections 2Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 2Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 3Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 4
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that ... announced its latest designs of 2014 mother of ... elegant outfits are offered with big discounts, up to ... October 30 can enjoy this special offer. , ... it has become one of the leading brands in ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... But overall odds are still low and headache sufferers ... -- Migraines are more common in women with multiple sclerosis ... , The study looked at close to 117,000 U.S. women ... had been diagnosed with migraine at the start of the ...
... problem, researcher says , TUESDAY, Feb. 16 (HealthDay News) ... computation method is highly accurate in detecting a ... a new study. , More than 2 million Americans ... chambers quiver instead of beating effectively. This causes blood ...
... of death, recurrence halved for those who took it, study ... study of more than 4,000 women who were diagnosed with ... survival and reduce the risk of recurrence. , "Women who ... breast cancer [during the study follow-up period] than those who ...
... Feb. 16 Twenty-nine Clear ... 11-12 raising $2,792,094 for St. Jude Children,s Research ... research and treatment of pediatric cancer and other catastrophic diseases. Despite ... these stations last year by 11 percent. , "Radio listeners have ...
... 16 In these difficult times in Washoe County ... services into the Reno area.   The Newton ... Programs Inc. is providing cutting edge educational and therapeutic services to ... represents a net investment into the area. This means outside ...
... researchers have developed a hands-free alternative to cell phone texting ... it, make it safer," said Juan Gilbert, professor and chairman ... He said one problem with banning texting while driving ... said it will be difficult for police to can,t enforce ...
Cached Medicine News:Health News:Migraine Tied to Raised Multiple Sclerosis Risk 2Health News:In Tests, Implanted Monitor Detects Atrial Fibrillation 2Health News:Aspirin May Boost Breast Cancer Survival 2Health News:Aspirin May Boost Breast Cancer Survival 3Health News:29 Clear Channel stations Nationwide Raise Nearly $2.8 Million to Help Save the Lives of Kids Fighting Cancer and Other Deadly Diseases 2Health News:29 Clear Channel stations Nationwide Raise Nearly $2.8 Million to Help Save the Lives of Kids Fighting Cancer and Other Deadly Diseases 3Health News:Reno Children With Disabilities Profit From a Little Known but Internationally Recognized Non-Profit Organization as it Quietly Crosses the $200,000.00 Mark in Service Investment Into the Reno Area 2
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
... national reference laboratory and a laboratory ... an extensive test menu of highly ... clinical and anatomic pathology. Owned by ... clients include university teaching hospitals and ...
Sharp tipped scissors angled 135 from the shaft with a horizontal cutting action. For cutting in the plane parallel to the retina and cutting membranes adherent to the retinal surface (delamination)....
Medicine Products: